SafeGuard Surgical

SafeGuard Surgical is a private, pre-revenue medical device innovator building a scalable platform around its flagship product, LeakGuard™, a biodegradable stent with FDA Breakthrough Device designation. The company's mission is to revolutionize post-operative care by preventing surgical leaks, thereby improving patient survival, reducing hospital costs, and minimizing medical waste. Founded by surgeon-entrepreneur Dr. Scott Kelley and backed by individual investors including notable figures from sports and philanthropy, the company is positioning its technology as a new standard of care across multiple surgical applications. Its initial focus is in ophthalmology, with clear expansion potential into other surgical fields where anastomotic leaks are a critical challenge.

A scalable platform centered on biodegradable stent technology (LeakGuard™) designed to prevent surgical anastomotic leaks, reduce complications, eliminate the need for device removal, and minimize medical waste across multiple surgical applications.

SafeGuard competes in the broad surgical sealants, adhesives, and stent market dominated by large-cap medtech players like Baxter, BD, J&J (Ethicon), and Medtronic. Its differentiation hinges on the combined value proposition of active leak prevention *and* biodegradability, a niche not fully addressed by current standard-of-care products which often require removal or are passive barriers.